ArticleNature communications2021
Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Seroprevalence of SARS-CoV-2 Antibodies in Africa: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- SARS-CoV-2 transmission among children and staff in daycare centres during a nationwide lockdown in France: a cross-sectional, multicentre, seroprevalence study.The Lancet. Child & adolescent health · 2021Trial
- Mobility-driven synthetic contact matrices as a scalable solution for real-time pandemic response modeling.Nature communications · 2026Article
- Household exposure, demographic and health characteristics associated with SARS-CoV-2 infection in a cohort study in Northern France.Scientific reports · 2025Article
- Seroprevalence of SARS-CoV-2 antibodies in Ethiopia: findings from the 2022 national population-based survey (second round).BMC infectious diseases · 2025Article
- Use of cell phone data to correct Île-de-France population estimates and SARS-CoV-2 incidence, July to September, 2021: a proof-of-concept exercise.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Planning and adjusting the COVID-19 booster vaccination campaign to reduce disease burden.Infectious Disease Modelling · 2025Article
- Sero-prevalence of SARS-CoV-2 antibodies in Ethiopia: Results of the National Population Based Survey, 2021.PloS one · 2025Article
- Molecular epidemiology and population immunity of SARS-CoV-2 in Guangdong (2022-2023) following a pivotal shift in the pandemic.Nature communications · 2024Article
- Key Challenges for Respiratory Virus Surveillance while Transitioning out of Acute Phase of COVID-19 Pandemic.Emerging infectious diseases · 2024Article
- Risk Factors for Community and Intrahousehold Transmission of SARS-CoV-2: Modeling in a Nationwide French Population-Based Cohort Study, the EpiCoV Study.American journal of epidemiology · 2024Article
- The impact of spatial connectivity on NPIs effectiveness.BMC infectious diseases · 2024Article
- Application of Machine Learning Prediction of Individual SARS-CoV-2 Vaccination and Infection Status to the French Serosurveillance Survey From March 2020 to 2022: Cross-Sectional Study.JMIR public health and surveillance · 2023Article
- Risk of SARS-CoV-2 Infection Among Households With Children in France, 2020-2022.JAMA network open · 2023Article
- Epidemiological inference for emerging viruses using segregating sites.Nature communications · 2023Article
- Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia.The Journal of experimental medicine · 2023Article
- Monitoring Temporal Changes in SARS-CoV-2 Spike Antibody Levels and Variant-Specific Risk for Infection, Dominican Republic, March 2021-August 2022.Emerging infectious diseases · 2023Article
- Specific COVID-19 risk behaviors and the preventive effect of personal protective equipment among healthcare workers in Japan.Global health & medicine · 2023Article
- Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region.iScience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Assessment of the cumulative incidence of SARS-CoV-2 infections is critical for monitoring the course and extent of the COVID-19 epidemic. Here, we report estimated seroprevalence in the French population and the proportion of infected individuals who developed neutralising antibodies at three points throughout the first epidemic wave. Testing 11,000 residual specimens for anti-SARS-CoV-2 IgG and neutralising antibodies, we find nationwide seroprevalence of 0.41% (95% CI: 0.05-0.88) mid-March, 4.14% (95% CI: 3.31-4.99) mid-April and 4.93% (95% CI: 4.02-5.89) mid-May 2020. Approximately 70% of seropositive individuals have detectable neutralising antibodies. Infection fatality rate is 0.84% (95% CI: 0.70-1.03) and increases exponentially with age. These results confirm that the nationwide lockdown substantially curbed transmission and that the vast majority of the French population remained susceptible to SARS-CoV-2 in May 2020. Our study shows the progression of the first epidemic wave and provides a framework to inform the ongoing public health response as viral transmission continues globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.